

Global Nuclide Drugs Market Research Report 2024(Status and Outlook)

<https://marketpublishers.com/r/G34EB99C7869EN.html>

Date: December 2024

Pages: 149

Price: US\$ 2,800.00 (Single User License)

ID: G34EB99C7869EN

Abstracts

Report Overview

Nuclide drugs, also known as radiopharmaceuticals, are a class of pharmaceuticals containing radioactive isotopes used in diagnostic and therapeutic procedures. These drugs play a crucial role in nuclear medicine, enabling the visualization and treatment of various medical conditions. Nuclide drugs are characterized by their ability to emit radiation that can be detected externally, aiding in the diagnosis and monitoring of diseases such as cancer, cardiovascular disorders, and neurological conditions.

The current market size for nuclide drugs in 2023 is estimated at approximately USD 5.6 billion. The market is projected to grow at a Compound Annual Growth Rate (CAGR) of 8.73% from 2024 to 2032. This growth can be attributed to several key factors driving the market forward.

One of the primary growth drivers for the nuclide drugs market is the increasing prevalence of cancer and other chronic diseases worldwide. As the global population ages and lifestyles change, the incidence of cancer and other diseases requiring nuclear medicine interventions is on the rise. This trend is expected to fuel the demand for nuclide drugs in the coming years.

Technological advancements in imaging techniques and radiopharmaceutical development are also contributing to market growth. Innovations in nuclear imaging modalities such as PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography) have expanded the applications of nuclide drugs, making them more effective in diagnosing and treating various conditions.

Moreover, growing investments in healthcare infrastructure, particularly in emerging economies, are creating opportunities for market expansion. Improved access to nuclear medicine facilities and increasing awareness about the benefits of nuclide drugs are driving market growth in regions with previously limited healthcare resources.

In terms of market trends, personalized medicine is gaining traction in the nuclide drugs sector. Tailoring treatment plans based on individual patient characteristics and genetic profiles is becoming increasingly important in healthcare. Nuclide drugs play a significant role in personalized medicine by enabling targeted therapies and precise diagnostic imaging, leading to better patient outcomes.

Furthermore, there is a growing emphasis on theranostics, which combines diagnostic imaging and targeted therapy using radiopharmaceuticals. Theranostic approaches allow healthcare providers to diagnose conditions accurately and deliver personalized treatments, ultimately improving patient care and treatment efficacy.

Regionally, North America and Europe currently dominate the nuclide drugs market due to well-established healthcare systems, high adoption rates of advanced medical technologies, and significant investments in research and development. However, Asia-Pacific is expected to witness the fastest growth in the coming years, driven by increasing healthcare expenditure, rising awareness about nuclear medicine, and expanding access to advanced healthcare services.

Despite the promising growth prospects, the nuclide drugs market faces several challenges. Regulatory hurdles related to the approval and manufacturing of radiopharmaceuticals, reimbursement issues, and concerns about radiation exposure are key challenges that industry players need to address. Overcoming these obstacles will be crucial for sustaining market growth and ensuring the safe and effective use of nuclide drugs in clinical practice.

This report provides a deep insight into the global Nuclide Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the

Global Nuclide Drugs Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Nuclide Drugs market in any manner.

Global Nuclide Drugs Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

GE Healthcare

Cardinal Health

Curium Pharma

Lantheus Medical Imaging

Inc.

Eczac?ba?? Monrol Nuclear Products

Novartis International AG

Siemens

China Isotope & Radiation

Yantai Dongcheng Pharmaceutical

Jubilant Life Sciences

Bracco

Market Segmentation (by Type)

Technetium-99

Iodine-123

Iodine-125

Iodine-131

Fluorine-18

Gallium-67

Others

Market Segmentation (by Application)

Therapeutic Use

Diagnostic Use

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa,

Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Nuclide Drugs Market

Overview of the regional outlook of the Nuclide Drugs Market:

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value (USD Billion) data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Nuclide Drugs Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.

Chapter 12 is the main points and conclusions of the report.

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

1.1 Market Definition and Statistical Scope of Nuclide Drugs

1.2 Key Market Segments

1.2.1 Nuclide Drugs Segment by Type

1.2.2 Nuclide Drugs Segment by Application

1.3 Methodology & Sources of Information

1.3.1 Research Methodology

1.3.2 Research Process

1.3.3 Market Breakdown and Data Triangulation

1.3.4 Base Year

1.3.5 Report Assumptions & Caveats

2 NUCLIDE DRUGS MARKET OVERVIEW

2.1 Global Market Overview

2.1.1 Global Nuclide Drugs Market Size (M USD) Estimates and Forecasts (2019-2032)

2.1.2 Global Nuclide Drugs Sales Estimates and Forecasts (2019-2032)

2.2 Market Segment Executive Summary

2.3 Global Market Size by Region

2.4 Macroeconomic Analysis

3 NUCLIDE DRUGS MARKET COMPETITIVE LANDSCAPE

3.1 Global Nuclide Drugs Sales by Manufacturers (2019-2024)

3.2 Global Nuclide Drugs Revenue Market Share by Manufacturers (2019-2024)

3.3 Nuclide Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.4 Global Nuclide Drugs Average Price by Manufacturers (2019-2024)

3.5 Manufacturers Nuclide Drugs Sales Sites, Area Served, Product Type

3.6 Nuclide Drugs Market Competitive Situation and Trends

3.6.1 Nuclide Drugs Market Concentration Rate

3.6.2 Global 5 and 10 Largest Nuclide Drugs Players Market Share by Revenue

3.6.3 Mergers & Acquisitions, Expansion

4 NUCLIDE DRUGS INDUSTRY CHAIN ANALYSIS

- 4.1 Nuclide Drugs Industry Chain Analysis
- 4.2 Market Overview of Key Raw Materials
- 4.3 Midstream Market Analysis
- 4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF NUCLIDE DRUGS MARKET

- 5.1 Key Development Trends
- 5.2 Driving Factors
- 5.3 Market Challenges
- 5.4 Market Restraints
- 5.5 Industry News
 - 5.5.1 New Product Developments
 - 5.5.2 Mergers & Acquisitions
 - 5.5.3 Expansions
 - 5.5.4 Collaboration/Supply Contracts
- 5.6 Industry Policies

6 NUCLIDE DRUGS MARKET SEGMENTATION BY TYPE

- 6.1 Evaluation Matrix of Segment Market Development Potential (Type)
- 6.2 Global Nuclide Drugs Sales Market Share by Type (2019-2024)
- 6.3 Global Nuclide Drugs Market Size Market Share by Type (2019-2024)
- 6.4 Global Nuclide Drugs Price by Type (2019-2024)

7 NUCLIDE DRUGS MARKET SEGMENTATION BY APPLICATION

- 7.1 Evaluation Matrix of Segment Market Development Potential (Application)
- 7.2 Global Nuclide Drugs Market Sales by Application (2019-2024)
- 7.3 Global Nuclide Drugs Market Size (M USD) by Application (2019-2024)
- 7.4 Global Nuclide Drugs Sales Growth Rate by Application (2019-2024)

8 NUCLIDE DRUGS MARKET SALES BY REGION

- 8.1 Global Nuclide Drugs Sales by Region
 - 8.1.1 Global Nuclide Drugs Sales by Region
 - 8.1.2 Global Nuclide Drugs Sales Market Share by Region
- 8.2 Global Nuclide Drugs Market Size by Region
 - 8.2.1 Global Nuclide Drugs Market Size by Region

8.2.2 Global Nuclide Drugs Market Size Market Share by Region

8.3 North America

8.3.1 North America Nuclide Drugs Sales by Country

8.3.2 North America Nuclide Drugs Market Size by Country

8.3.3 U.S. Market Overview

8.3.4 Canada Market Overview

8.3.5 Mexico Market Overview

8.4 Europe

8.4.1 Europe Nuclide Drugs Sales by Country

8.4.2 Europe Nuclide Drugs Market Size by Country

8.4.3 Germany Market Overview

8.4.4 France Market Overview

8.4.5 U.K. Market Overview

8.4.6 Italy Market Overview

8.4.7 Russia Market Overview

8.5 Asia Pacific

8.5.1 Asia Pacific Nuclide Drugs Sales by Region

8.5.2 China

8.5.3 Japan

8.5.4 South Korea

8.5.5 India

8.5.6 Southeast Asia

8.6 Asia Pacific

8.6.1 Asia Pacific Nuclide Drugs Market Size by Region

8.6.2 Asia Pacific Nuclide Drugs Market Size by Region

8.6.3 China

8.6.4 Japan

8.6.5 South Korea

8.6.6 India

8.6.7 Southeast Asia

8.7 South America

8.7.1 South America Nuclide Drugs Sales by Country

8.7.2 South America Nuclide Drugs Market Size by Country

8.7.3 Brazil

8.7.4 Argentina

8.7.5 Columbia

8.8 Middle East and Africa

8.8.1 Middle East and Africa Nuclide Drugs Sales by Region

8.8.2 Middle East and Africa Nuclide Drugs Market Size by Region

8.8.3 Saudi Arabia

8.8.4 UAE

8.8.5 Egypt

8.8.6 Nigeria

8.8.7 South Africa

9 NUCLIDE DRUGS MARKET PRODUCTION BY REGION

9.1 Global Production of Nuclide Drugs by Region (2019-2024)

9.2 Global Nuclide Drugs Revenue Market Share by Region (2019-2024)

9.3 Global Nuclide Drugs Production, Revenue, Price and Gross Margin (2019-2024)

9.4 North America Nuclide Drugs Production

9.4.1 North America Nuclide Drugs Production Growth Rate (2019-2024)

9.4.2 North America Nuclide Drugs Production, Revenue, Price and Gross Margin (2019-2024)

9.5 Europe Nuclide Drugs Production

9.5.1 Europe Nuclide Drugs Production Growth Rate (2019-2024)

9.5.2 Europe Nuclide Drugs Production, Revenue, Price and Gross Margin (2019-2024)

9.6 Japan Nuclide Drugs Production (2019-2024)

9.6.1 Japan Nuclide Drugs Production Growth Rate (2019-2024)

9.6.2 Japan Nuclide Drugs Production, Revenue, Price and Gross Margin (2019-2024)

9.7 China Nuclide Drugs Production (2019-2024)

9.7.1 China Nuclide Drugs Production Growth Rate (2019-2024)

9.7.2 China Nuclide Drugs Production, Revenue, Price and Gross Margin (2019-2024)

10 KEY COMPANIES PROFILE

10.1 GE Healthcare

10.1.1 GE Healthcare Nuclide Drugs Basic Information

10.1.2 GE Healthcare Nuclide Drugs Product Overview

10.1.3 GE Healthcare Nuclide Drugs Product Market Performance

10.1.4 GE Healthcare Business Overview

10.1.5 GE Healthcare Nuclide Drugs SWOT Analysis

10.1.6 GE Healthcare Recent Developments

10.2 Cardinal Health

10.2.1 Cardinal Health Nuclide Drugs Basic Information

10.2.2 Cardinal Health Nuclide Drugs Product Overview

10.2.3 Cardinal Health Nuclide Drugs Product Market Performance

- 10.2.4 Cardinal Health Business Overview
- 10.2.5 Cardinal Health Nuclide Drugs SWOT Analysis
- 10.2.6 Cardinal Health Recent Developments
- 10.3 Curium Pharma
 - 10.3.1 Curium Pharma Nuclide Drugs Basic Information
 - 10.3.2 Curium Pharma Nuclide Drugs Product Overview
 - 10.3.3 Curium Pharma Nuclide Drugs Product Market Performance
 - 10.3.4 Curium Pharma Nuclide Drugs SWOT Analysis
 - 10.3.5 Curium Pharma Business Overview
 - 10.3.6 Curium Pharma Recent Developments
- 10.4 Lantheus Medical Imaging
 - 10.4.1 Lantheus Medical Imaging Nuclide Drugs Basic Information
 - 10.4.2 Lantheus Medical Imaging Nuclide Drugs Product Overview
 - 10.4.3 Lantheus Medical Imaging Nuclide Drugs Product Market Performance
 - 10.4.4 Lantheus Medical Imaging Business Overview
 - 10.4.5 Lantheus Medical Imaging Recent Developments
- 10.5 Inc.
 - 10.5.1 Inc. Nuclide Drugs Basic Information
 - 10.5.2 Inc. Nuclide Drugs Product Overview
 - 10.5.3 Inc. Nuclide Drugs Product Market Performance
 - 10.5.4 Inc. Business Overview
 - 10.5.5 Inc. Recent Developments
- 10.6 Eczac?ba?? Monrol Nuclear Products
 - 10.6.1 Eczac?ba?? Monrol Nuclear Products Nuclide Drugs Basic Information
 - 10.6.2 Eczac?ba?? Monrol Nuclear Products Nuclide Drugs Product Overview
 - 10.6.3 Eczac?ba?? Monrol Nuclear Products Nuclide Drugs Product Market Performance
 - 10.6.4 Eczac?ba?? Monrol Nuclear Products Business Overview
 - 10.6.5 Eczac?ba?? Monrol Nuclear Products Recent Developments
- 10.7 Novartis International AG
 - 10.7.1 Novartis International AG Nuclide Drugs Basic Information
 - 10.7.2 Novartis International AG Nuclide Drugs Product Overview
 - 10.7.3 Novartis International AG Nuclide Drugs Product Market Performance
 - 10.7.4 Novartis International AG Business Overview
 - 10.7.5 Novartis International AG Recent Developments
- 10.8 Siemens
 - 10.8.1 Siemens Nuclide Drugs Basic Information
 - 10.8.2 Siemens Nuclide Drugs Product Overview
 - 10.8.3 Siemens Nuclide Drugs Product Market Performance

- 10.8.4 Siemens Business Overview
- 10.8.5 Siemens Recent Developments
- 10.9 China Isotope and Radiation
 - 10.9.1 China Isotope and Radiation Nuclide Drugs Basic Information
 - 10.9.2 China Isotope and Radiation Nuclide Drugs Product Overview
 - 10.9.3 China Isotope and Radiation Nuclide Drugs Product Market Performance
 - 10.9.4 China Isotope and Radiation Business Overview
 - 10.9.5 China Isotope and Radiation Recent Developments
- 10.10 Yantai Dongcheng Pharmaceutical
 - 10.10.1 Yantai Dongcheng Pharmaceutical Nuclide Drugs Basic Information
 - 10.10.2 Yantai Dongcheng Pharmaceutical Nuclide Drugs Product Overview
 - 10.10.3 Yantai Dongcheng Pharmaceutical Nuclide Drugs Product Market Performance
 - 10.10.4 Yantai Dongcheng Pharmaceutical Business Overview
 - 10.10.5 Yantai Dongcheng Pharmaceutical Recent Developments
- 10.11 Jubilant Life Sciences
 - 10.11.1 Jubilant Life Sciences Nuclide Drugs Basic Information
 - 10.11.2 Jubilant Life Sciences Nuclide Drugs Product Overview
 - 10.11.3 Jubilant Life Sciences Nuclide Drugs Product Market Performance
 - 10.11.4 Jubilant Life Sciences Business Overview
 - 10.11.5 Jubilant Life Sciences Recent Developments
- 10.12 Bracco
 - 10.12.1 Bracco Nuclide Drugs Basic Information
 - 10.12.2 Bracco Nuclide Drugs Product Overview
 - 10.12.3 Bracco Nuclide Drugs Product Market Performance
 - 10.12.4 Bracco Business Overview
 - 10.12.5 Bracco Recent Developments

11 NUCLIDE DRUGS MARKET FORECAST BY REGION

- 11.1 Global Nuclide Drugs Market Size Forecast
- 11.2 Global Nuclide Drugs Market Forecast by Region
 - 11.2.1 North America Market Size Forecast by Country
 - 11.2.2 Europe Nuclide Drugs Market Size Forecast by Country
 - 11.2.3 Asia Pacific Nuclide Drugs Market Size Forecast by Region
 - 11.2.4 South America Nuclide Drugs Market Size Forecast by Country
 - 11.2.5 Middle East and Africa Forecasted Sales of Nuclide Drugs by Country

12 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2032)

12.1 Global Nuclide Drugs Market Forecast by Type (2025-2032)

12.1.1 Global Forecasted Sales of Nuclide Drugs by Type (2025-2032)

12.1.2 Global Nuclide Drugs Market Size Forecast by Type (2025-2032)

12.1.3 Global Forecasted Price of Nuclide Drugs by Type (2025-2032)

12.2 Global Nuclide Drugs Market Forecast by Application (2025-2032)

12.2.1 Global Nuclide Drugs Sales (K MT) Forecast by Application

12.2.2 Global Nuclide Drugs Market Size (M USD) Forecast by Application
(2025-2032)

13 CONCLUSION AND KEY FINDINGS

I would like to order

Product name: Global Nuclide Drugs Market Research Report 2024(Status and Outlook)

Product link: <https://marketpublishers.com/r/G34EB99C7869EN.html>

Price: US\$ 2,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G34EB99C7869EN.html>